Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients

Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients

BackgroundKidney transplant recipients (KTR) are at increased risk of cancer due to chronic immunosuppression. Non-melanoma skin cancer has an excess risk of approximately 250 times higher than the general population. Moreover, in solid organ transplant recipients (SOTR) these cancers have a more ag...

Full description

Bibliographic Details
Main Authors: T. Van Meerhaeghe, J.F. Baurain, O. Bechter, C. Orte Cano, V. Del Marmol, A. Devresse, P. Doubel, M. Hanssens, R. Hellemans, D. Lienard, A. Rutten, B. Sprangers, A. Le Moine, S. Aspeslagh
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Nephrology
Subjects:
cemiplimab
kidney transplant recipients
cutaneous squamous cell carcinoma
immune checkpoint inhibitors
rejection
Online Access:https://www.frontiersin.org/articles/10.3389/fneph.2022.1041819/full

Internet

https://www.frontiersin.org/articles/10.3389/fneph.2022.1041819/full

Similar Items